Are Markov and semi-Markov Models Flexible Enough for Cognitive Panel Data?

Richard J. Kryscio and Erin L. Abner

Abstract

Markov chains and semi-Markov models are standard tools used to describe the flow of subjects from health into various stages of a disease. Applications of these techniques face challenges, when modeling the flow of elderly subjects through cognitive states into dementia, due to the interval censoring of the entry into cognitive states, the transient nature of pre-dementia cognitive states, time-dependent risk factors, missing data, selection bias, and clinical diagnoses that may not agree with the gold standard diagnoses obtained at autopsy. There is a need to make these tools more flexible, if they are to be used effectively, when analyzing cognitive panel data.

The purpose of this editorial is to discuss the use of Markov chains and semi-Markov processes to analyze panel data that routinely arise, when modeling the flow of elderly subjects from cognitively intact into impaired cognitive states, including various forms of Mild Cognitive Impairment (MCI) and the absorbing state of dementia. While these approaches have been used successfully to model the flow of subjects through various health states associated with cancer and AIDS, their application to dementing diseases presents challenges not necessarily encountered in these other contexts.

Panel Data

Serial annual cognitive assessments minimize participant burden and practice effects, but introduce interval censoring, since conversions to impaired cognitive states occur between visits. The time interval between visits is often one year, but could be longer [1,2]. In addition, since these are elderly subjects, the effect of the competing risks of death and drop out is significant, and missed visits occur frequently. This is a natural setting for the use of semi-Markov models, since they can accommodate a mix of interval censoring for important transitions and exact times for deaths, as well as missed visits [3]. However, these applications have assumed that transitions are to the right (in one direction), and there are no time dependent covariates, such as strokes or late-life depression that might impact transitions [4,5].

Selection Bias

Participants in panel studies may be asked to donate their brains upon death, and/or contribute serial cerebrospinal fluid samples, and/or undergo neuroimaging to help identify early biomarkers for the disease. Not all participants volunteer for these studies, which creates missing data/selection bias issues. Even without biomarkers, this bias frequently occurs since almost all panel studies are observational studies of volunteers, which creates a healthy cohort effect. For example, cohorts that do not allow seriously impaired elderly to enroll create significant bias, when identifying risks for transition to dementia [6].

Classifying Cognitive States

Dementia is currently incurable, and the dearth of therapy trial’s success is not due to lack of effort or resources, but rather to the insidious nature of the underlying diseases. Recent data show that the Alzheimer’s Disease (AD) process (thinning of the neuronal structure in the pre-frontal cortex of the brain) begins years prior to a clinical diagnosis of AD, as evidenced by a heavier amyloid load observed in neuroimages of the brain decades, before dementia onset [7,8]. Therefore, current emphasis is on transitions into pre-dementia states, with the target being to identify and possibly treat groups of subjects who are at a high risk for mild impairments [9,10].

There is little unanimity on the definition of an impaired state, with terms like age associated memory impairment, not seriously cognitively impaired, and MCI appearing in various studies. Even the currently popular MCI state has various definitions depending on the criteria used to define it (amnestic MCI, mixed MCI, MCI due to AD, etc.). Complex clinical criteria lead to MCI states that rarely involve backflow, while simpler criteria, such as poor performance on cognitive tests, lead to transient states with significant backflow between serial assessments [11] (Figure 1). This has serious modeling consequences, since only Markov chains are flexible enough to handle backflow.

The use of random effects in the Markov chain, first introduced by Salazar et al. [12], leads to issues related to estimating the random effects, when making predictions on the next subjects flow into and out of impaired MCI states. And even in these models, as Song et al. [13] demonstrated by introducing a scaling parameter into a random effects model for a Markov chain with backflow to show how to identify subjects who might undergo such reversions, multiple considerations remain. This approach can accommodate the use of time-dependent covariates, but this complicates the arithmetic, when studying the long run behavior of the chain [14].

Finally, concordance studies between clinical and neuropathological...
diagnoses show that misclassification of the etiology of clinical impairments is common [15]. The risk factors for pure Alzheimer’s disease, for example, likely differ from a mixed dementia, involving both AD and Lewy body disease, both of which likely differ from those for vascular dementia. This etiological misclassification tends to dilute the effect of a risk factor, depending heavily on the correlation between the clinical and neuropathological diagnoses within a study.

In closing, with the current emphasis on discovering who is at risk for dementing diseases like AD well before dementia occurs, the modeling of risk factors for dementia relying on traditional tools of Markov and semi-Markov processes presents challenges to the biostatistician. Since AD is now the sixth leading cause of death in the United States, and since the number of cases is rising exponentially [16,17], the problems outlined above are worth pursuing.

**Funding**

This research was partially funded with support from the following grants to the University of Kentucky’s Center on Aging: R01 AG038651-01A1 and P30 AG028383 from the National Institute on Aging, as well as a grant to the University of Kentucky’s Center for Clinical and Translational Science, UL1TR000117, from the National Center for Advancing Translational Sciences.

**References**


